Industry Strength Score
56/100
Composite price performance score based on 3, 6, and 12-month returns, with more weight on recent trends.
BEYONDSPRING INC (BYSI) Stock Price & Overview
NASDAQ:BYSI • KYG108301006
Current stock price
1.6256 USD
+0.12 (+7.66%)
At close:
1.6175 USD
-0.01 (-0.5%)
After Hours:
The current stock price of BYSI is 1.6256 USD. Today BYSI is up by 7.66%. In the past month the price decreased by -6.79%. In the past year, price decreased by -10.65%.
BYSI Key Statistics
52-Week Range1.21 - 3.44
Current BYSI stock price positioned within its 52-week range.
1-Month Range1.42 - 1.84
Current BYSI stock price positioned within its 1-month range.
- Market Cap
- 66.845M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.03
- Dividend Yield
- N/A
BYSI Stock Performance
Today
+7.66%
1 Week
-13.22%
1 Month
-6.79%
3 Months
-1.95%
Longer-term
6 Months -24.12%
1 Year -10.65%
2 Years -24.88%
3 Years +55.91%
5 Years -86.01%
10 Years N/A
BYSI Stock Chart
BYSI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to BYSI. When comparing the yearly performance of all stocks, BYSI is a bad performer in the overall market: 76.89% of all stocks are doing better.
Chartmill TA Rating
Chartmill Setup Rating
BYSI Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to BYSI. Both the profitability and financial health of BYSI have multiple concerns.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
BYSI Earnings
Next Earnings DateMay 13, 2026
Last Earnings DateMar 25, 2026
PeriodQ4 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %
BYSI Forecast & Estimates
Analysts
Analysts85.71
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A
BYSI Index Membership
BYSI is currently included in the following stock indexes tracked on ChartMill.
BYSI Financial Highlights
Over the last trailing twelve months BYSI reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS increased by 92.59% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-1.01M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -3.88% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
Chartmill High Growth Momentum
EPS Q2Q%-50%
Sales Q2Q%N/A
EPS 1Y (TTM)92.59%
Revenue 1Y (TTM)N/A
BYSI Ownership
Ownership
Inst Owners14.57%
Shares41.12M
Float34.97M
Ins Owners14.96%
Short Float %6.27%
Short Ratio120.16
BYSI Industry Overview
BYSI operates in the Biotechnology sub-industry within the Health Care sector. This group contains 416 stocks and is scored by ChartMill on both price strength and growth momentum.
Industry Growth Score
14/100
Composite growth score based on earnings growth, revenue growth, and profitability across the sub-industry.
Relative Performance
Each rank shows how many other sub-industries were outperformed over that timeframe.
1 Month Rank
66%
Outperformed 66% of sub-industries
3 Month Rank
48%
Outperformed 48% of sub-industries
6 Month Rank
32%
Outperformed 32% of sub-industries
Industry Fundamentals & Breadth
- Members
- 416
- New Highs
- 5.8%
- New Lows
- 3.1%
- Average ROE
- 48.3%
- Average Profit Margin
- 20.9%
- Average Operating Margin
- 33.6%
- Average P/E
- 26.2
- Average Fwd P/E
- 22.5
- Average Debt/Equity
- 2.1
BYSI Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.37 | 349.666B | ||
| AMGN | AMGEN INC | 14.63 | 183.263B | ||
| GILD | GILEAD SCIENCES INC | 14.5 | 160.44B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 21.6 | 109.41B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.62 | 77.363B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.15 | 40.311B | ||
| INSM | INSMED INC | N/A | 29.127B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.701B | ||
| NTRA | NATERA INC | N/A | 28.37B | ||
| BIIB | BIOGEN INC | 11.63 | 26.913B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.51 | 24.944B | ||
| INCY | INCYTE CORP | 10.68 | 19.451B | ||
| MRNA | MODERNA INC | N/A | 18.695B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About BYSI
Company Profile
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Company Info
IPO: 2017-03-09
BEYONDSPRING INC
100 Campus Drive, West Side, 4Th Floor, Suite 410
Florham Park NEW JERSEY 10005 US
CEO: Lan Huang
Employees: 40
Phone: 16465284184
BEYONDSPRING INC / BYSI FAQ
What does BYSI do?
BeyondSpring, Inc. engages in the development and commercialization of immuno-oncology cancer therapies. The company is headquartered in Florham Park, New Jersey and currently employs 40 full-time employees. The company went IPO on 2017-03-09. The firm is focused on developing therapies to improve clinical outcomes for patients with high unmet medical needs. Its lead asset, Plinabulin, is in late-stage clinical development as an anti-cancer agent in non-small cell lung cancer (NSCLC) and a range of cancer indications. The Company’s mechanism of action as a dendritic cell maturation agent supports both anti-cancer activity and immune modulation, offering an approach to resensitizing tumors to checkpoint inhibitors. The company also has a pipeline of immuno-oncology product candidates, BPI-002 program, which is based on an oral small molecule agent that increases T-cell co-stimulation; BPI-003 program, which is based on a small molecule inhibitor of IKK, a protein kinase, and BPI-004 program, which is focused on a small molecule that induces the production of neo-antigens by tumor cells, allowing tumors containing no immune cells to be infiltrated by the immune system.
Can you provide the latest stock price for BEYONDSPRING INC?
The current stock price of BYSI is 1.6256 USD. The price increased by 7.66% in the last trading session.
Does BEYONDSPRING INC pay dividends?
BYSI does not pay a dividend.
What is the ChartMill rating of BEYONDSPRING INC stock?
BYSI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Which stock exchange lists BYSI stock?
BYSI stock is listed on the Nasdaq exchange.
What is the next earnings date for BYSI stock?
BEYONDSPRING INC (BYSI) will report earnings on 2026-05-13.
Can you provide the ownership details for BYSI stock?
You can find the ownership structure of BEYONDSPRING INC (BYSI) on the Ownership tab.